Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2409021 After Escalating Single Oral Dose Administration in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2015
At a glance
- Drugs Adomeglivant (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly
- 07 Jun 2017 Biomarkers information updated
- 27 May 2012 Additional location (Singapore), actual initiation date (May 2007) added and official title amended as reported by ClinicalTrials.gov.
- 27 May 2012 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History